Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Oral Health

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Perceptions of medical doctors on bisphosphonate-related osteonecrosis of the jaw

BMC Oral HealthBMC series – open, inclusive and trusted201616:92

https://doi.org/10.1186/s12903-016-0290-0

Received: 11 February 2016

Accepted: 29 August 2016

Published: 7 September 2016

Abstract

Background

This study aimed to investigate medical doctors’ awareness of bisphosphonate-related osteonecrosis of the jaw (BRONJ) and the status of dental referrals.

Methods

Self-administered questionnaires were distributed to medical doctors practicing internal medicine, family medicine, and orthopedics at the 6 tertiary medical centers located in Seoul, Korea. The survey consisted of 22 questions regarding the general characteristics, bisphosphonate therapy, awareness of BRONJ, and implementation of dental referrals.

Results

Among 192 medical doctors, 21.9 % had not heard of the disease. Only 8.9 % correctly answered all 5 questions testing BRONJ knowledge. Dental referrals made by medical doctors were implemented in less than 30 % of the total patients. Oncology specialists most often recognized the necessity of dental referrals followed in decreasing order by endocrinology, rheumatology, family medicine, and orthopedic specialists.

Conclusion

Given medical doctors’ low BRONJ perception and implementation level of dental referrals, enhancing information dissemination on BRONJ and development of a highly accessible educational program recognizing the need for dental referrals are urgent.

Keywords

Osteonecrosis of the JawBisphosphonateAwarenessQuestionnaireDoctor

Background

Bisphosphonates (BP) are a class of drugs used in the treatment and prevention of various bone diseases, such as osteoporosis, osteitis deformans, multiple myeloma, osteogenesis imperfecta, and bone metastases, by suppressing osteoclast-mediated bone resorption through apoptosis of osteoclasts [1]. Due to the drug’s safety and strong bone-specific inhibitory effect on osteoclastic activity, BPs have effectively been used for decades [2, 3]. However, in the recent years, there has been a serious adverse effect of jaw necrosis associated with the administration of BPs [4, 5]. Although the pathophysiology of jaw necrosis due to drug use is not yet been fully understood, significant inhibition of bone remodeling based on the drug’s pharmacological effect has been considered to be the main cause [68].

After the first report of bisphosphonate-related osteonecrosis of the jaw (BRONJ) in 2003 [4], the American Association of Oral and Maxillofacial Surgeons (AAOMS) defined BRONJ in their 2009 position paper as “necrotic bone exposure in the maxillofacial region lasting for more than 8 weeks in patients with previous or current administration of BP and with no history of radiation therapy” [9]. In the latest position paper in 2014, AAOMS modified the term into medication-related osteonecrosis of the jaw (MRONJ) to emphasize the role of drugs causing osteonecrosis of the jaw [7]. The incidence of BRONJ has been reported to be 0.01 to 6.7 % [7]. Considering the worldwide trend of increasing BP therapy and high BP dependence, the incidence is expected to continuously grow [10]. Although the treatment modalities are not established, most researchers have recommended conservative approaches and the additional use of growth factors or hormone therapy [7, 11].

In 2009, Park et al. [12] reported that only 56.5 % of Korean dentists were aware of BRONJ, and another study reported similar awareness in dental hygienists [13]. Therefore, efforts to increase the awareness of BRONJ among oral health professionals have been made, emphasizing the importance of prevention of the disease and research on intractable osteonecrosis of the jaw.

However, there have been few studies on medical doctors’ awareness of BRONJ and how well dental referrals are being carried out. As in other forms of osteonecrosis, such as osteoradionecrosis and osteomyelitis of jaw, BRONJ usually has a poor prognosis and demands long-term treatment, thus mutual efforts between the medical doctor and dentist through a multi-disciplinary approach are essential in the diagnosis, treatment, and prevention of BRONJ [14]. Therefore, this study aimed to investigate the awareness of BRONJ among medical doctors who prescribe BPs and the current situation of dental referrals in the multi-disciplinary treatment and prevention of BRONJ.

Methods

Among 17 tertiary medical institutions in Seoul, Korea which are registered with the Health Insurance Review Agency as of July of 2015, 6 were selected based on a random sampling method. The subjects from the selected institutions were medical specialists and residents of internal medicine (endocrinology, rheumatology, oncology), family medicine, and orthopedics who agreed to participate in the study.

The number of subjects was determined to be 172 based on Cohen’s sample size calculations with a power of more than 90 % and a significance level of 0.05 (two-sided test). After accounting for dropouts from the study, a total of 200 subjects were used [15]. The study was carried out by visiting the participating institutions and distributing self-administered questionnaires. After thoroughly explaining the purpose and content of the study, the surveys were given out to only those who voluntarily chose to participate in the study. Surveys that were not collected on the same day of distribution were collected during another visit to the institutions or were sent through mail. Of the 200 surveys, 192 were used in the analysis after excluding 4 uncollected surveys and 4 surveys with insufficient answers. This study was approved by the Ethics Committee of Ewha Womans University, Seoul, Korea (15-16B-16).

In the study, the terminology ‘BRONJ’ rather than ‘MRONJ’ or ‘ARONJ’ (antiresorptive-related osteonecrosis of the jaw) was used. Considering that the target sample of this survey was medical doctors who do not treat ONJ themselves and are unfamiliar with the relatively novel terminology MRONJ, the term BRONJ was preferentially used. Also, because antiresorptive agents include not only BP and monoclonal antibodies, but also calcitonin, estrogens, and selective estrogen receptor modulators, the authors considered the terminology BRONJ rather than ARONJ to be more appropriate for this study.

The survey was comprised of a total of 22 questions. Personal information was not included. First, the surveys were categorized according to the specialties: internal medicine (endocrinology, rheumatology, oncology), family medicine, and orthopedics. Period of career was divided into the following: (1) less than 5 years, (2) between 5 and 10 years, (3) between 10 and 20 years, and (4) more than 20 years. Questions regarding BP treatment, the reason for administration, the doctors’ level of awareness, and dental examination and referrals were also included in the questionnaire. (See Additional file 1) The medical doctors’ understanding of BRONJ was evaluated using the AAOMS guidelines, consisting of questions regarding the definition, staging, treatment, and prevention of the disease, and the discontinuation of BP [7].

Descriptive statistics were utilized for the general characteristics of samples, BP therapy, experience with BRONJ patients, and the doctors’ sources on BRONJ information. For evaluating the degree of understanding, 1 point was given for each correct answer to the questions regarding the definition, staging, treatment, prevention, and drug discharge. No points were given when the subject answered incorrectly or by answering ‘I do not know.’ Higher points correspond to higher level of understanding. The group differences in level of understanding were evaluated according to job characteristics, BP indication, administration route, and experience of BRONJ patients.

For evaluating the degree of dental referrals, the question was based on a 5-point scale with answer choices of ‘before’, ‘during’, and ‘after BP administration’. When 100 % of patients requiring BP administration were being referred to dentists, 5 points were given, and on the other hand, when less than 10 % were being referred, 1 point was given. The reasons for not referring patients to dentists were presented, and the group differences of dental referrals were evaluated according to job characteristics, BP indication, administration route, doctor’s awareness, and experience with BRONJ patients.

Statistical analyses were performed using SPSS 20.0 (SPSS Inc., Chicago, IL, USA). Frequency and percentage analysis, chi-square test, independent sample T-test, and one-way analysis of variance were performed. For post hoc testing, Scheffe’s test was used. All values were considered statistically significant when P < 0.05.

Results

General characteristics of the 192 surveyed medical doctors, BP therapy, and experience with BRONJ patients are summarized in Table 1. In the question regarding awareness of BRONJ, 150 doctors (78.1 %) answered “heard of the disease,” and 42 (21.9 %) answered “have not heard of the disease.” Medical specialists were more aware of BRONJ compared to residents (P < 0.01), and the highest level of awareness was seen in the group with more than 20 years of work experience, followed by less than 5 years, between 10 and 20 years, and between 5 and 10 years (P < 0.01). On the other hand, there was no significant difference between the areas of specialty. The majority of participants (38 %) responded that the source from which they acquired awareness of the disease was academic journals, followed by educational seminars (30 %), books (20 %), newspapers (5 %), internet (4 %), and others, such as from colleagues, or patient experiences (3 %).
Table 1

General characteristics of surveyed medical doctors, bisphosphonate (BP) therapy and experience of bisphosphonate-related osteonecrosis of the jaw (BRONJ) patients (n = 192)

 

Group

N

Percent

Position

Specialists

114

59.4

Residents

78

40.6

Specialty

Family medicine

50

26.1

Orthopedics

55

28.6

Internal Medicine

87

45.3

Period of Career

<5 years

69

35.9

5 ~ 10 years

33

17.2

10 ~ 20 years

36

18.8

>20 years

54

28.1

Indications for BP use

Osteoporosis

160

83.3

Cancer

31

16.2

Others

1

0.5

Administration route of BP

Intravenous

63

32.8

Oral

127

66.2

Other

2

1.0

Other adjuvant medications used with BP

Corticosteroids

20

10.4

Chemotherapy

22

11.5

None

150

78.1

Number of patients on BP prescription per month

1–10

111

57.8

11–20

26

13.5

Over 21

55

28.7

Experience of patients with BRONJ

Yes

53

27.6

No

115

59.9

Do not know

24

12.5

Number of patients with BRONJ (n = 53)

1–3

35

66.0

3–6

16

30.2

Over 6

2

3.8

To determine the level of BRONJ understanding, 5 questions concerning the definition, staging, drug discontinuation, prevention, and proper management of the disease were included. Only 17 doctors (8.9 %) answered all 5 questions correctly, and 20.9 % (n = 21) received zero points. Medical specialists had higher scores compared to residents, and the group with 10 to 20 years of work experience had the highest level of BRONJ knowledge (P < 0.01). Also, medical doctors who had experience with BRONJ patients showed a significantly higher awareness score.(P < 0.01). However, there was no statistically significant difference in the level of BRONJ knowledge between the areas of specialty (P > 0.05; Table 2).
Table 2

Assessment of Knowledge on bisphosphonate-related osteonecrosis of the jaw (BRONJ)

  

BRONJ Knowledge

P value

N

M ± SD

Position

Specialist

78

1.99 ± 1.392

.001

Resident

114

2.66 ± 1.314

 

Period of Career

<5 years

69

1.88 ± 1.40

.002

5 ~ 10 years

33

2.45 ± 1.23

 

10 ~ 20 years

36

2.83 ± 1.38

 

>20 years

54

2.63 ± 1.31

 

Specialty

Family medicine

50

2.52 ± 1.58

.106

Orthopedics

55

2.04 ± 1.32

 

Internal medicine

87

2.37 ± 1.39

 

Experience of BRONJ patients

Yes

53

3.04 ± 1.34

<0.001

No

139

2.14 ± 1.49

 

Indications for use (n = 191)

Osteoporosis

160

2.26 ± 1.319

.009

Cancer

31

2.97 ± 1.602

 

M mean score of total correct answers on BRONJ

According to the 5-point scale, the degree of dental referrals for BP administration was 1.86 ± 1.2 before administration, 1.99 ± 1.2 during administration, and 1.78 ± 1.1 after administration. The results were not significantly different according to the participants’ position and period of career. On the other hand, based on the areas of specialty, before BP administration (P < 0.01), during administration (P < 0.01), and after administration (P < 0.05), all displayed statistically significant differences with internal medicine showing the highest degree of dental referrals, followed by family medicine and orthopedics. Also, the group with BRONJ awareness and prescribing BP to prevent bone metastases showed a higher degree of dental referrals (P < 0.01) compared to the group prescribing the drug for treatment of osteoporosis.

The perception of the necessity of dental referrals according to the areas of specialty was highest in oncology (4.30 ± 1.08), followed by endocrinology (3.65 ± 0.98), rheumatology (3.44 ± 1.42), family medicine (3.36 ± 1.22), and orthopedics (3.12 ± 1.21) (P < .05). However, the degree of dental referrals did not show a statistically significant difference among the areas of specialty (P > 0.05). The reasons for not making dental referrals differed among the specialties (Fig. 1). In family medicine, endocrinology, and rheumatology, the majority answered that they did not feel the necessity of dental referrals; in orthopedics, it was difficult to earn patient cooperation due to financial, time, and motivational issues; and in oncology, they thought that the treatment of systemic disease was more urgent than dental treatment.
Fig. 1

Reasons why medical doctors do not make dental referrals

Discussion

Since the first report of BRONJ in 2003, there have been various clinical and experimental studies, yet much of the treatment and prognosis of the disease remain unknown [16]. Considering the refractory progress of BRONJ, it has widely been accepted that the best measure for BRONJ treatment is prevention. Therefore it is critical for medical doctors to implement dental referrals for pre-evaluation of oral health and dental risk factors before administering BP [7, 14, 17].

In 2005, the FDA attempted to increase BRONJ awareness among healthcare providers by adding a warning statement of possible osteonecrosis of the jaw through administration of BP. However, in this study, 21.9 % of the medical doctors surveyed had not heard of the disease, and only 9.9 % correctly answered all 5 questions, indicating a very limited BRONJ awareness.

The knowledge score was significantly higher in doctors who had experience with BRONJ patients. This could be due to their efforts to obtain more information relevant to the cases that they have handled. As a result, the need for educating those who showed lower scores is paramount particularly if they have not handled actual cases. Encountering the development of ONJ before proper education and through understanding of the disease could lead to poor medical practice. Considering that knowledge of BRONJ was acquired mainly through academic journals (38.5 %) and educational seminars (30.3 %), continuous educational publications and development of highly accessible educational programs for medical doctors are deemed urgent and necessary.

Kholsa et al. [11] and Lam et al. [17] reported that management of periodontal disease and oral hygiene are most important in patients who require treatment with BP, thus emphasizing the necessity of informing them of the risk of BRONJ and importance of performing dental treatment before and during drug administration. However, according to the present study, the percentage of dental referrals before, during, and after the administration of BP remains low, in less than 30 % of total patients. Given the reasons for not making dental referrals according to the area of specialty as stated previously, the need to express the extreme importance for dental examination and generate a well-coordinated referral system is recommended through open communication and exchange of expertise from both fields.

Several studies recommended that thorough history taking, mutual exchange between the dentist and medical specialist, and providing detailed information of BRONJ to patients are essential to its prevention [14, 16]. For the prevention of BRONJ, unsalvageable teeth are recommended to be extracted before starting BP treatment [7, 14]. Also, if all dental procedures are performed prior to BP administration, future invasive procedures such as dental extractions can be prevented. Preventive measures for optimal oral health can lead to a decrease in the number of BRONJ patients [7].

A limitation of this study is that the subjects were 192 medical doctors selected through random sampling in tertiary hospitals, therefore the authors cannot declare with certainty that the sample represents all medical doctors nor can the authors exclude selection bias. Further studies with a sufficient sample size and joint research with the other medical societies would provide more reliable results.

Conclusion

Through this study, it was shown that the medical doctors’ awareness of BRONJ was low. Based on the finding that only 30 % of patients taking BPs are referred to dentists, these results are valuable as basic educational data to not only express the urgency and severity of BRONJ to medical doctors but to emphasize the utmost importance of prevention through mutual communication between dentists and medical doctors as well.

Abbreviations

AAOMS: 

American Association of Oral and Maxillofacial Surgeons

BP: 

Bisphosphonates

BRONJ: 

Bisphosphonate-related osteonecrosis of the jaw

FDA: 

Food and Drug Administration

MRONJ: 

Medication-related osteonecrosis of the jaw

Declarations

Acknowledgements

We would like to thank former professor, Dr. Myung-Rae Kim for his dedicated help during the study as a dissertation examiner.

Funding

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (NRF-2016R1C1B2006270).

Availability of data and materials

The full dataset supporting the conclusions of this article can be obtained upon request to the corresponding author at Pf. Sun-Jong Kim, oralsurgeonsj@gmail.com.

Authors’ contributions

JWK and SRJ made substantial contributions to the study conception and design, and acquisition of data, data interpretation, and prepared the manuscript. SJK were involved in study conception and design, critical revising of the manuscript. YSK was involved manuscript preparation, and critical revising. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests. This article was based on the dissertation of SR Jeong from Ewha Womans University, Graduate School of Clinical Dentistry under the guidance of Pf. Sun-Jong Kim.

Consent for publication

Not applicable.

Ethics approval and consent to participate

This study was approved by the Ethics Committee of Ewha Womans University, Seoul, Korea (15-16B-16). Consent to participate was waived for the reason that the research presents no more than minimal risk of harm to participants (i.e., the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests) and involves no procedures for which written consent is normally required outside of the research context.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Graduate School of Clinical Dentistry, Ewha Womans University, Seoul, Korea; Research Institute for Intractable Osteonecrosis of the Jaw, School of Medicine, Ewha Womans University
(2)
Department of Medical & Pharmaceutical Science, Sookmyung Women’s University
(3)
Department of Oral & Maxillofacial Surgery, Ewha Womans University Medical Center

References

  1. Allen MR, Burr DB. Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don’t know. Bone. 2011;49:56–65.View ArticlePubMedGoogle Scholar
  2. Chan AS. Ten years of alendronate treatment for osteoporosis in postmenopausal women. N Engl J Med. 2004;351:190–2.View ArticlePubMedGoogle Scholar
  3. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19:733–59.View ArticlePubMedGoogle Scholar
  4. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115–7.View ArticlePubMedGoogle Scholar
  5. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527–34.View ArticlePubMedGoogle Scholar
  6. Armamento-Villareal R, Napoli N, Panwar V, Novack D. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med. 2006;355:2048–50.View ArticlePubMedGoogle Scholar
  7. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014;72:1938–56.View ArticlePubMedGoogle Scholar
  8. Cremers S, Farooki A. Biochemical markers of bone turnover in osteonecrosis of the jaw in patients with osteoporosis and advanced cancer involving the bone. Ann N Y Acad Sci. 2011;1218:80–7.View ArticlePubMedGoogle Scholar
  9. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg. 2009;67:2–12.View ArticlePubMedGoogle Scholar
  10. Lee JK, Kim K-W, Choi J-Y, Moon S-Y, Kim S-G, Kim C-H, Kim H-M, Kwon Y-D, Kim Y-D, Lee D-K, et al. Bisphosphonates-related osteonecrosis of the jaw in Korea: a preliminary report. J Korean Assoc Oral Maxillofac Surg. 2013;39:9–13.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479–91.View ArticlePubMedGoogle Scholar
  12. Yong-Duck P, Young-Ran K, Deog-Yoon K, Yoon-Sok C, Jeung-Keun L, Yeo-Gab K, Yong-Dae K. Awareness of Korean dentists on bisphosphonate related osteonecrosis of the jaws: preliminary report. J Korean Assoc Oral Maxillofac Surg. 2009;35:153–7.Google Scholar
  13. Gyeon-Yeon Kang. A survey on the cognizance and perceptions of BRONJ among the dental hygienists in Seoul. Master thesis, Ewha Womans University, Graduate School of Clinical Dentistry; 2014.Google Scholar
  14. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30:3–23.View ArticlePubMedGoogle Scholar
  15. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175–91.View ArticlePubMedGoogle Scholar
  16. Reid IR, Cornish J. Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol. 2012;8:90–6.Google Scholar
  17. Lam DK, Sandor GK, Holmes HI, Evans AW, Clokie CM. A review of bisphosphonate-associated osteonecrosis of the jaws and its management. J Can Dent Assoc. 2007;73:417–22.PubMedGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement